{'_id': ObjectId('65bd5cb8a297dcc878bb52df'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['First-generation antihistamines', ['Brompheniramine', 'Carbinoxamine', 'Chlorpheniramine', 'Clemastine', 'Cyproheptadine', 'Dexbrompheniramine', 'Dexchlorpheniramine', 'Dimenhydrinate', 'Diphenhydramine (oral)', 'Doxylamine', 'Hydroxyzine', 'Meclizine', 'Promethazine', 'Pyrilamine', 'Triprolidine']]], 'Rationale': 'Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity\nUse of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate.', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52e0'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antiparkinsonian agents', ['Benztropine (oral)', 'Trihexyphenidyl']]], 'Rationale': 'Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52e1'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antispasmodics', ['Atropine (excludes ophthalmic)', 'Belladonna alkaloids', 'Clidinium-chlordiazepoxide', 'Dicyclomine Homatropine (excludes opthalmic)', 'Hyoscyamine', 'Methscopolamine', 'Propantheline', 'Scopolamine', 'Doxazosin']]], 'Rationale': 'Highly anticholinergic, uncertain effectiveness', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52e2'), 'Organ System, Therapeutic Category, Drug(s)': ['Antithrombotics', ['Dipyridamole, oral short acting (does not apply to the extended-release combination with aspirin)', []]], 'Rationale': 'May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52e3'), 'Organ System, Therapeutic Category, Drug(s)': ['Anti-infective', ['Nitrofurantoin', []]], 'Rationale': 'Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available', 'Recommendation': 'Avoid in individuals with creatinine clearance <30 mL/min or for long-term suppression', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52e4'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Peripheral alpha-1 blockers for treatment of hypertension', ['Prazosin', 'Terazosin', 'Guanabenz']]], 'Rationale': 'High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/beneﬁt proﬁle', 'Recommendation': 'Avoid use as an antihypertensive', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52e5'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Central alpha-agonists', []]], 'Rationale': '', 'Recommendation': 'Avoid as ﬁrst-line antihypertensive', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52e6'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Clonidine for ﬁrst-line treatment of hypertension\nOther CNS alpha-agonists', ['Guanfacine', 'Methyldopa', 'Reserpine (>0.1 mg/day)', 'Amitriptyline']]], 'Rationale': 'High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension', 'Recommendation': 'Avoid other CNS alpha-agonists as listed', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52e7'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Disopyramide', []]], 'Rationale': 'May induce heart failure in older adults because of potent negative inotropic action; strongly anticholinergic; other antiarrhythmic drugs preferred', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52e8'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Dronedarone', []]], 'Rationale': 'Worse outcomes have been reported in patients taking dronedarone who have permanent atrial ﬁbrillation or severe or recently decompensated heart failure.', 'Recommendation': 'Avoid in individuals with permanent atrial ﬁbrillation or severe or recently decompensated heart failure', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52e9'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Digoxin for ﬁrst-line treatment of atrial ﬁbrillation or of heart failure', []]], 'Rationale': 'Use in atrial ﬁbrillation: should not be used as ﬁrst-line agent in atrial ﬁbrillation, because there are safer and more effective alternatives for rate control supported by high-quality evidence.\nUse in heart failure: evidence for beneﬁts and harms of digoxin is conﬂicting and of lower quality; most but not all of the evidence concerns use in HFrEF. There is strong evidence for other agents as ﬁrst-line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional beneﬁt and may increase risk of toxicity.\nDecreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with stage or chronic kidney disease.', 'Recommendation': 'Avoid this rate control agent as ﬁrst- line therapy for atrial ﬁbrillation\nAvoid as ﬁrst-line therapy for heart failure\nIf used for atrial ﬁbrillation or heart failure, avoid dosages >0.125 mg/day >0.', 'Quality of Evidence': 'Atrial ﬁbrillation:', 'Strenght of Recommendation': 'Atrial ﬁbrillation:'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52ea'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Nifedipine, immediate release', []]], 'Rationale': 'Potential for hypotension; risk of precipitating myocardial ischemia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52eb'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Amiodarone', []]], 'Rationale': 'Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial ﬁbrillation; may be reasonable ﬁrst-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control', 'Recommendation': 'Avoid as ﬁrst-line therapy for atrial ﬁbrillation unless patient has heart failure or substantial left ventricular hypertrophy', 'Quality of Evidence': 'Heart failure:', 'Strenght of Recommendation': 'Heart failure:'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52ec'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antidepressants, alone or in combination', ['Amoxapine', 'Clomipramine', 'Desipramine', 'Doxepin >6 mg/day', 'Imipramine', 'Nortriptyline', 'Paroxetine', 'Protriptyline', 'Trimipramine', 'Amobarbital']]], 'Rationale': 'Highly anticholinergic, sedating, and cause orthostatic hypotension; safety proﬁle of low-dose doxepin (≤6 mg/day) comparable to that of placebo', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52ed'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antipsychotics, ﬁrst (conventional) and second (atypical) generation', []]], 'Rationale': 'Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia\nAvoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others', 'Recommendation': 'Avoid, except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy', 'Quality of Evidence': 'Dosage', 'Strenght of Recommendation': 'Dosage'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52ee'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Barbiturates', ['Butabarbital', 'Butalbital', 'Mephobarbital', 'Pentobarbital', 'Phenobarbital', 'Secobarbital', 'Alprazolam']]], 'Rationale': 'High rate of physical dependence, tolerance to sleep beneﬁts, greater risk of overdose at low dosages', 'Recommendation': 'Avoid', 'Quality of Evidence': '>.125 mg/day:', 'Strenght of Recommendation': '>.125 mg/day:'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52ef'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Benzodiazepines', ['Estazolam', 'Lorazepam', 'Oxazepam', 'Temazepam', 'Triazolam', 'Chlordiazepoxide (alone or in combination with amitriptyline or clidinium)', 'Clonazepam', 'Clorazepate', 'Diazepam', 'Flurazepam', 'Quazepam', 'Eszopiclone']]], 'Rationale': 'Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long- acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults\nMay be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'moderate', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52f0'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Meprobamate', []]], 'Rationale': 'High rate of physical dependence; sedating', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52f1'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”)', ['Zaleplon', 'Zolpidem', 'Methyltestosterone']]], 'Rationale': 'Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (ie, drugs) have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/ hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52f2'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Ergoloid mesylates (dehydrogenated ergot alkaloids)\nIsoxsuprine', []]], 'Rationale': 'Lack of efﬁcacy', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52f3'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Androgens', ['Testosterone', 'Chlorpropamide']]], 'Rationale': 'Potential for cardiac problems; contraindicated in men with prostate cancer', 'Recommendation': 'Avoid unless indicated for conﬁrmed hypogonadism with clinical symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52f4'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Desiccated thyroid', []]], 'Rationale': 'Concerns about cardiac effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52f5'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Estrogens with or without progestins', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid systemic estrogen (eg, oral and topical patch) nt Vaginal cream or vaginal tablets: acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52f6'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Growth hormone', []]], 'Rationale': 'Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose', 'Recommendation': 'Avoid, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deﬁciency due to an established etiology', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52f7'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Insulin, sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin)', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52f8'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Megestrol', []]], 'Rationale': 'Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52f9'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Sulfonylureas, long acting', ['Glimepiride', 'Glyburide (also known as glibenclamide)', 'Aspirin >325 mg/day']]], 'Rationale': 'Chlorpropamide: prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Weak'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52fa'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Metoclopramide', []]], 'Rationale': 'Glimepiride and glyburide: higher risk of severe prolonged hypoglycemia in older adults\nCan cause extrapyramidal effects, including tardive dyskinesia; risk may be greater in frail older adults and with prolonged exposure', 'Recommendation': 'Avoid, unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52fb'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Mineral oil, given orally', []]], 'Rationale': 'Potential for aspiration and adverse effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Oral and patch:', 'Strenght of Recommendation': 'Oral and patch:'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52fc'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Proton-pump inhibitors', []]], 'Rationale': 'Risk of Clostridium difﬁcile infection and bone loss and fractures', 'Recommendation': 'Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)', 'Quality of Evidence': 'high', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52fd'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Meperidine', []]], 'Rationale': 'Oral analgesic not effective in dosages commonly used; may have higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Vaginal cream', 'Strenght of Recommendation': 'Topical vaginal'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52fe'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Non–cyclooxygenase-selective NSAIDs, oral:', ['Diclofenac', 'Diﬂunisal', 'Etodolac', 'Fenoprofen', 'Ibuprofen', 'Ketoprofen', 'Meclofenamate', 'Mefenamic acid', 'Meloxicam', 'Nabumetone', 'Naproxen', 'Oxaprozin', 'Piroxicam', 'Sulindac', 'Tolmetin', 'Carisoprodol']]], 'Rationale': 'Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for', 'Recommendation': 'Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)', 'Quality of Evidence': 'or vaginal', 'Strenght of Recommendation': 'cream or tablets:'}
{'_id': ObjectId('65bd5cb9a297dcc878bb52ff'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Indomethacin\nKetorolac, includes parenteral', []]], 'Rationale': '3-6 months and in ~2%-4% of patients treated for year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. \nRisks are dose related.\nIncreased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'tablets:', 'Strenght of Recommendation': 'weak'}
{'_id': ObjectId('65bd5cb9a297dcc878bb5300'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Skeletal muscle relaxants', ['Chlorzoxazone', 'Cyclobenzaprine', 'Metaxalone', 'Methocarbamol', 'Orphenadrine']]], 'Rationale': 'Indomethacin is more likely than other NSAIDs to have adverse CNS effects. Of all the NSAIDs, indomethacin has the most adverse effects.\nMost muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65bd5cb9a297dcc878bb5301'), 'Organ System, Therapeutic Category, Drug(s)': ['Genitourinary', ['Desmopressin', []]], 'Rationale': 'High risk of hyponatremia; safer alternative treatments', 'Recommendation': 'Avoid for treatment of nocturia or nocturnal polyuria', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14178c1e3e6427ddabf'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['First-generation antihistamines', ['Brompheniramine', 'Carbinoxamine', 'Chlorpheniramine', 'Clemastine', 'Cyproheptadine', 'Dexbrompheniramine', 'Dexchlorpheniramine', 'Dimenhydrinate', 'Diphenhydramine (oral)', 'Doxylamine', 'Hydroxyzine', 'Meclizine', 'Promethazine', 'Pyrilamine', 'Triprolidine']]], 'Rationale': 'Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity\nUse of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate.', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14278c1e3e6427ddac0'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antiparkinsonian agents', ['Benztropine (oral)', 'Trihexyphenidyl']]], 'Rationale': 'Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14278c1e3e6427ddac1'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antispasmodics', ['Atropine (excludes ophthalmic)', 'Belladonna alkaloids', 'Clidinium-chlordiazepoxide', 'Dicyclomine Homatropine (excludes opthalmic)', 'Hyoscyamine', 'Methscopolamine', 'Propantheline', 'Scopolamine', 'Doxazosin']]], 'Rationale': 'Highly anticholinergic, uncertain effectiveness', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14278c1e3e6427ddac2'), 'Organ System, Therapeutic Category, Drug(s)': ['Antithrombotics', ['Dipyridamole, oral short acting (does not apply to the extended-release combination with aspirin)', []]], 'Rationale': 'May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddac3'), 'Organ System, Therapeutic Category, Drug(s)': ['Anti-infective', ['Nitrofurantoin', []]], 'Rationale': 'Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available', 'Recommendation': 'Avoid in individuals with creatinine clearance <30 mL/min or for long-term suppression', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddac4'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Peripheral alpha-1 blockers for treatment of hypertension', ['Prazosin', 'Terazosin', 'Guanabenz']]], 'Rationale': 'High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/beneﬁt proﬁle', 'Recommendation': 'Avoid use as an antihypertensive', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddac5'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Central alpha-agonists', []]], 'Rationale': '', 'Recommendation': 'Avoid as ﬁrst-line antihypertensive', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddac6'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Clonidine for ﬁrst-line treatment of hypertension\nOther CNS alpha-agonists', ['Guanfacine', 'Methyldopa', 'Reserpine (>0.1 mg/day)', 'Amitriptyline']]], 'Rationale': 'High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension', 'Recommendation': 'Avoid other CNS alpha-agonists as listed', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddac7'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Disopyramide', []]], 'Rationale': 'May induce heart failure in older adults because of potent negative inotropic action; strongly anticholinergic; other antiarrhythmic drugs preferred', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddac8'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Dronedarone', []]], 'Rationale': 'Worse outcomes have been reported in patients taking dronedarone who have permanent atrial ﬁbrillation or severe or recently decompensated heart failure.', 'Recommendation': 'Avoid in individuals with permanent atrial ﬁbrillation or severe or recently decompensated heart failure', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddac9'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Digoxin for ﬁrst-line treatment of atrial ﬁbrillation or of heart failure', []]], 'Rationale': 'Use in atrial ﬁbrillation: should not be used as ﬁrst-line agent in atrial ﬁbrillation, because there are safer and more effective alternatives for rate control supported by high-quality evidence.\nUse in heart failure: evidence for beneﬁts and harms of digoxin is conﬂicting and of lower quality; most but not all of the evidence concerns use in HFrEF. There is strong evidence for other agents as ﬁrst-line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional beneﬁt and may increase risk of toxicity.\nDecreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with stage or chronic kidney disease.', 'Recommendation': 'Avoid this rate control agent as ﬁrst- line therapy for atrial ﬁbrillation\nAvoid as ﬁrst-line therapy for heart failure\nIf used for atrial ﬁbrillation or heart failure, avoid dosages >0.125 mg/day >0.', 'Quality of Evidence': 'Atrial ﬁbrillation:', 'Strenght of Recommendation': 'Atrial ﬁbrillation:'}
{'_id': ObjectId('65cce14378c1e3e6427ddaca'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Nifedipine, immediate release', []]], 'Rationale': 'Potential for hypotension; risk of precipitating myocardial ischemia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddacb'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Amiodarone', []]], 'Rationale': 'Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial ﬁbrillation; may be reasonable ﬁrst-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control', 'Recommendation': 'Avoid as ﬁrst-line therapy for atrial ﬁbrillation unless patient has heart failure or substantial left ventricular hypertrophy', 'Quality of Evidence': 'Heart failure:', 'Strenght of Recommendation': 'Heart failure:'}
{'_id': ObjectId('65cce14378c1e3e6427ddacc'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antidepressants, alone or in combination', ['Amoxapine', 'Clomipramine', 'Desipramine', 'Doxepin >6 mg/day', 'Imipramine', 'Nortriptyline', 'Paroxetine', 'Protriptyline', 'Trimipramine', 'Amobarbital']]], 'Rationale': 'Highly anticholinergic, sedating, and cause orthostatic hypotension; safety proﬁle of low-dose doxepin (≤6 mg/day) comparable to that of placebo', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddacd'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antipsychotics, ﬁrst (conventional) and second (atypical) generation', []]], 'Rationale': 'Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia\nAvoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others', 'Recommendation': 'Avoid, except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy', 'Quality of Evidence': 'Dosage', 'Strenght of Recommendation': 'Dosage'}
{'_id': ObjectId('65cce14378c1e3e6427ddace'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Barbiturates', ['Butabarbital', 'Butalbital', 'Mephobarbital', 'Pentobarbital', 'Phenobarbital', 'Secobarbital', 'Alprazolam']]], 'Rationale': 'High rate of physical dependence, tolerance to sleep beneﬁts, greater risk of overdose at low dosages', 'Recommendation': 'Avoid', 'Quality of Evidence': '>.125 mg/day:', 'Strenght of Recommendation': '>.125 mg/day:'}
{'_id': ObjectId('65cce14378c1e3e6427ddacf'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Benzodiazepines', ['Estazolam', 'Lorazepam', 'Oxazepam', 'Temazepam', 'Triazolam', 'Chlordiazepoxide (alone or in combination with amitriptyline or clidinium)', 'Clonazepam', 'Clorazepate', 'Diazepam', 'Flurazepam', 'Quazepam', 'Eszopiclone']]], 'Rationale': 'Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long- acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults\nMay be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'moderate', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddad0'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Meprobamate', []]], 'Rationale': 'High rate of physical dependence; sedating', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddad1'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”)', ['Zaleplon', 'Zolpidem', 'Methyltestosterone']]], 'Rationale': 'Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (ie, drugs) have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/ hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddad2'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Ergoloid mesylates (dehydrogenated ergot alkaloids)\nIsoxsuprine', []]], 'Rationale': 'Lack of efﬁcacy', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddad3'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Androgens', ['Testosterone', 'Chlorpropamide']]], 'Rationale': 'Potential for cardiac problems; contraindicated in men with prostate cancer', 'Recommendation': 'Avoid unless indicated for conﬁrmed hypogonadism with clinical symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddad4'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Desiccated thyroid', []]], 'Rationale': 'Concerns about cardiac effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddad5'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Estrogens with or without progestins', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid systemic estrogen (eg, oral and topical patch) nt Vaginal cream or vaginal tablets: acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddad6'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Growth hormone', []]], 'Rationale': 'Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose', 'Recommendation': 'Avoid, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deﬁciency due to an established etiology', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddad7'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Insulin, sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin)', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddad8'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Megestrol', []]], 'Rationale': 'Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14378c1e3e6427ddad9'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Sulfonylureas, long acting', ['Glimepiride', 'Glyburide (also known as glibenclamide)', 'Aspirin >325 mg/day']]], 'Rationale': 'Chlorpropamide: prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Weak'}
{'_id': ObjectId('65cce14378c1e3e6427ddada'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Metoclopramide', []]], 'Rationale': 'Glimepiride and glyburide: higher risk of severe prolonged hypoglycemia in older adults\nCan cause extrapyramidal effects, including tardive dyskinesia; risk may be greater in frail older adults and with prolonged exposure', 'Recommendation': 'Avoid, unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14478c1e3e6427ddadb'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Mineral oil, given orally', []]], 'Rationale': 'Potential for aspiration and adverse effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Oral and patch:', 'Strenght of Recommendation': 'Oral and patch:'}
{'_id': ObjectId('65cce14478c1e3e6427ddadc'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Proton-pump inhibitors', []]], 'Rationale': 'Risk of Clostridium difﬁcile infection and bone loss and fractures', 'Recommendation': 'Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)', 'Quality of Evidence': 'high', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce14478c1e3e6427ddadd'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Meperidine', []]], 'Rationale': 'Oral analgesic not effective in dosages commonly used; may have higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Vaginal cream', 'Strenght of Recommendation': 'Topical vaginal'}
{'_id': ObjectId('65cce14478c1e3e6427ddade'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Non–cyclooxygenase-selective NSAIDs, oral:', ['Diclofenac', 'Diﬂunisal', 'Etodolac', 'Fenoprofen', 'Ibuprofen', 'Ketoprofen', 'Meclofenamate', 'Mefenamic acid', 'Meloxicam', 'Nabumetone', 'Naproxen', 'Oxaprozin', 'Piroxicam', 'Sulindac', 'Tolmetin', 'Carisoprodol']]], 'Rationale': 'Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for', 'Recommendation': 'Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)', 'Quality of Evidence': 'or vaginal', 'Strenght of Recommendation': 'cream or tablets:'}
{'_id': ObjectId('65cce14478c1e3e6427ddadf'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Indomethacin\nKetorolac, includes parenteral', []]], 'Rationale': '3-6 months and in ~2%-4% of patients treated for year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. \nRisks are dose related.\nIncreased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'tablets:', 'Strenght of Recommendation': 'weak'}
{'_id': ObjectId('65cce14478c1e3e6427ddae0'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Skeletal muscle relaxants', ['Chlorzoxazone', 'Cyclobenzaprine', 'Metaxalone', 'Methocarbamol', 'Orphenadrine']]], 'Rationale': 'Indomethacin is more likely than other NSAIDs to have adverse CNS effects. Of all the NSAIDs, indomethacin has the most adverse effects.\nMost muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce14478c1e3e6427ddae1'), 'Organ System, Therapeutic Category, Drug(s)': ['Genitourinary', ['Desmopressin', []]], 'Rationale': 'High risk of hyponatremia; safer alternative treatments', 'Recommendation': 'Avoid for treatment of nocturia or nocturnal polyuria', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d429b10b7452ebcee1'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['First-generation antihistamines', ['Brompheniramine', 'Carbinoxamine', 'Chlorpheniramine', 'Clemastine', 'Cyproheptadine', 'Dexbrompheniramine', 'Dexchlorpheniramine', 'Dimenhydrinate', 'Diphenhydramine (oral)', 'Doxylamine', 'Hydroxyzine', 'Meclizine', 'Promethazine', 'Pyrilamine', 'Triprolidine']]], 'Rationale': 'Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity\nUse of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate.', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d429b10b7452ebcee2'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antiparkinsonian agents', ['Benztropine (oral)', 'Trihexyphenidyl']]], 'Rationale': 'Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d529b10b7452ebcee3'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antispasmodics', ['Atropine (excludes ophthalmic)', 'Belladonna alkaloids', 'Clidinium-chlordiazepoxide', 'Dicyclomine Homatropine (excludes opthalmic)', 'Hyoscyamine', 'Methscopolamine', 'Propantheline', 'Scopolamine', 'Doxazosin']]], 'Rationale': 'Highly anticholinergic, uncertain effectiveness', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d529b10b7452ebcee4'), 'Organ System, Therapeutic Category, Drug(s)': ['Antithrombotics', ['Dipyridamole, oral short acting (does not apply to the extended-release combination with aspirin)', []]], 'Rationale': 'May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d529b10b7452ebcee5'), 'Organ System, Therapeutic Category, Drug(s)': ['Anti-infective', ['Nitrofurantoin', []]], 'Rationale': 'Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available', 'Recommendation': 'Avoid in individuals with creatinine clearance <30 mL/min or for long-term suppression', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcee6'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Peripheral alpha-1 blockers for treatment of hypertension', ['Prazosin', 'Terazosin', 'Guanabenz']]], 'Rationale': 'High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/beneﬁt proﬁle', 'Recommendation': 'Avoid use as an antihypertensive', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcee7'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Central alpha-agonists', []]], 'Rationale': '', 'Recommendation': 'Avoid as ﬁrst-line antihypertensive', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcee8'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Clonidine for ﬁrst-line treatment of hypertension\nOther CNS alpha-agonists', ['Guanfacine', 'Methyldopa', 'Reserpine (>0.1 mg/day)', 'Amitriptyline']]], 'Rationale': 'High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension', 'Recommendation': 'Avoid other CNS alpha-agonists as listed', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcee9'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Disopyramide', []]], 'Rationale': 'May induce heart failure in older adults because of potent negative inotropic action; strongly anticholinergic; other antiarrhythmic drugs preferred', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebceea'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Dronedarone', []]], 'Rationale': 'Worse outcomes have been reported in patients taking dronedarone who have permanent atrial ﬁbrillation or severe or recently decompensated heart failure.', 'Recommendation': 'Avoid in individuals with permanent atrial ﬁbrillation or severe or recently decompensated heart failure', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebceeb'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Digoxin for ﬁrst-line treatment of atrial ﬁbrillation or of heart failure', []]], 'Rationale': 'Use in atrial ﬁbrillation: should not be used as ﬁrst-line agent in atrial ﬁbrillation, because there are safer and more effective alternatives for rate control supported by high-quality evidence.\nUse in heart failure: evidence for beneﬁts and harms of digoxin is conﬂicting and of lower quality; most but not all of the evidence concerns use in HFrEF. There is strong evidence for other agents as ﬁrst-line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional beneﬁt and may increase risk of toxicity.\nDecreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with stage or chronic kidney disease.', 'Recommendation': 'Avoid this rate control agent as ﬁrst- line therapy for atrial ﬁbrillation\nAvoid as ﬁrst-line therapy for heart failure\nIf used for atrial ﬁbrillation or heart failure, avoid dosages >0.125 mg/day >0.', 'Quality of Evidence': 'Atrial ﬁbrillation:', 'Strenght of Recommendation': 'Atrial ﬁbrillation:'}
{'_id': ObjectId('65cce1d629b10b7452ebceec'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Nifedipine, immediate release', []]], 'Rationale': 'Potential for hypotension; risk of precipitating myocardial ischemia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce1d629b10b7452ebceed'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Amiodarone', []]], 'Rationale': 'Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial ﬁbrillation; may be reasonable ﬁrst-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control', 'Recommendation': 'Avoid as ﬁrst-line therapy for atrial ﬁbrillation unless patient has heart failure or substantial left ventricular hypertrophy', 'Quality of Evidence': 'Heart failure:', 'Strenght of Recommendation': 'Heart failure:'}
{'_id': ObjectId('65cce1d629b10b7452ebceee'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antidepressants, alone or in combination', ['Amoxapine', 'Clomipramine', 'Desipramine', 'Doxepin >6 mg/day', 'Imipramine', 'Nortriptyline', 'Paroxetine', 'Protriptyline', 'Trimipramine', 'Amobarbital']]], 'Rationale': 'Highly anticholinergic, sedating, and cause orthostatic hypotension; safety proﬁle of low-dose doxepin (≤6 mg/day) comparable to that of placebo', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce1d629b10b7452ebceef'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antipsychotics, ﬁrst (conventional) and second (atypical) generation', []]], 'Rationale': 'Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia\nAvoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others', 'Recommendation': 'Avoid, except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy', 'Quality of Evidence': 'Dosage', 'Strenght of Recommendation': 'Dosage'}
{'_id': ObjectId('65cce1d629b10b7452ebcef0'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Barbiturates', ['Butabarbital', 'Butalbital', 'Mephobarbital', 'Pentobarbital', 'Phenobarbital', 'Secobarbital', 'Alprazolam']]], 'Rationale': 'High rate of physical dependence, tolerance to sleep beneﬁts, greater risk of overdose at low dosages', 'Recommendation': 'Avoid', 'Quality of Evidence': '>.125 mg/day:', 'Strenght of Recommendation': '>.125 mg/day:'}
{'_id': ObjectId('65cce1d629b10b7452ebcef1'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Benzodiazepines', ['Estazolam', 'Lorazepam', 'Oxazepam', 'Temazepam', 'Triazolam', 'Chlordiazepoxide (alone or in combination with amitriptyline or clidinium)', 'Clonazepam', 'Clorazepate', 'Diazepam', 'Flurazepam', 'Quazepam', 'Eszopiclone']]], 'Rationale': 'Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long- acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults\nMay be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'moderate', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcef2'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Meprobamate', []]], 'Rationale': 'High rate of physical dependence; sedating', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcef3'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”)', ['Zaleplon', 'Zolpidem', 'Methyltestosterone']]], 'Rationale': 'Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (ie, drugs) have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/ hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcef4'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Ergoloid mesylates (dehydrogenated ergot alkaloids)\nIsoxsuprine', []]], 'Rationale': 'Lack of efﬁcacy', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcef5'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Androgens', ['Testosterone', 'Chlorpropamide']]], 'Rationale': 'Potential for cardiac problems; contraindicated in men with prostate cancer', 'Recommendation': 'Avoid unless indicated for conﬁrmed hypogonadism with clinical symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcef6'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Desiccated thyroid', []]], 'Rationale': 'Concerns about cardiac effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcef7'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Estrogens with or without progestins', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid systemic estrogen (eg, oral and topical patch) nt Vaginal cream or vaginal tablets: acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcef8'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Growth hormone', []]], 'Rationale': 'Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose', 'Recommendation': 'Avoid, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deﬁciency due to an established etiology', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcef9'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Insulin, sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin)', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcefa'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Megestrol', []]], 'Rationale': 'Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcefb'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Sulfonylureas, long acting', ['Glimepiride', 'Glyburide (also known as glibenclamide)', 'Aspirin >325 mg/day']]], 'Rationale': 'Chlorpropamide: prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Weak'}
{'_id': ObjectId('65cce1d629b10b7452ebcefc'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Metoclopramide', []]], 'Rationale': 'Glimepiride and glyburide: higher risk of severe prolonged hypoglycemia in older adults\nCan cause extrapyramidal effects, including tardive dyskinesia; risk may be greater in frail older adults and with prolonged exposure', 'Recommendation': 'Avoid, unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcefd'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Mineral oil, given orally', []]], 'Rationale': 'Potential for aspiration and adverse effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Oral and patch:', 'Strenght of Recommendation': 'Oral and patch:'}
{'_id': ObjectId('65cce1d629b10b7452ebcefe'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Proton-pump inhibitors', []]], 'Rationale': 'Risk of Clostridium difﬁcile infection and bone loss and fractures', 'Recommendation': 'Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)', 'Quality of Evidence': 'high', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce1d629b10b7452ebceff'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Meperidine', []]], 'Rationale': 'Oral analgesic not effective in dosages commonly used; may have higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Vaginal cream', 'Strenght of Recommendation': 'Topical vaginal'}
{'_id': ObjectId('65cce1d629b10b7452ebcf00'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Non–cyclooxygenase-selective NSAIDs, oral:', ['Diclofenac', 'Diﬂunisal', 'Etodolac', 'Fenoprofen', 'Ibuprofen', 'Ketoprofen', 'Meclofenamate', 'Mefenamic acid', 'Meloxicam', 'Nabumetone', 'Naproxen', 'Oxaprozin', 'Piroxicam', 'Sulindac', 'Tolmetin', 'Carisoprodol']]], 'Rationale': 'Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for', 'Recommendation': 'Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)', 'Quality of Evidence': 'or vaginal', 'Strenght of Recommendation': 'cream or tablets:'}
{'_id': ObjectId('65cce1d629b10b7452ebcf01'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Indomethacin\nKetorolac, includes parenteral', []]], 'Rationale': '3-6 months and in ~2%-4% of patients treated for year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. \nRisks are dose related.\nIncreased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'tablets:', 'Strenght of Recommendation': 'weak'}
{'_id': ObjectId('65cce1d629b10b7452ebcf02'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Skeletal muscle relaxants', ['Chlorzoxazone', 'Cyclobenzaprine', 'Metaxalone', 'Methocarbamol', 'Orphenadrine']]], 'Rationale': 'Indomethacin is more likely than other NSAIDs to have adverse CNS effects. Of all the NSAIDs, indomethacin has the most adverse effects.\nMost muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce1d629b10b7452ebcf03'), 'Organ System, Therapeutic Category, Drug(s)': ['Genitourinary', ['Desmopressin', []]], 'Rationale': 'High risk of hyponatremia; safer alternative treatments', 'Recommendation': 'Avoid for treatment of nocturia or nocturnal polyuria', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3525de55931cf3ed636'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['First-generation antihistamines', ['Brompheniramine', 'Carbinoxamine', 'Chlorpheniramine', 'Clemastine', 'Cyproheptadine', 'Dexbrompheniramine', 'Dexchlorpheniramine', 'Dimenhydrinate', 'Diphenhydramine (oral)', 'Doxylamine', 'Hydroxyzine', 'Meclizine', 'Promethazine', 'Pyrilamine', 'Triprolidine']]], 'Rationale': 'Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity\nUse of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate.', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3535de55931cf3ed637'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antiparkinsonian agents', ['Benztropine (oral)', 'Trihexyphenidyl']]], 'Rationale': 'Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3535de55931cf3ed638'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antispasmodics', ['Atropine (excludes ophthalmic)', 'Belladonna alkaloids', 'Clidinium-chlordiazepoxide', 'Dicyclomine Homatropine (excludes opthalmic)', 'Hyoscyamine', 'Methscopolamine', 'Propantheline', 'Scopolamine', 'Doxazosin']]], 'Rationale': 'Highly anticholinergic, uncertain effectiveness', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3535de55931cf3ed639'), 'Organ System, Therapeutic Category, Drug(s)': ['Antithrombotics', ['Dipyridamole, oral short acting (does not apply to the extended-release combination with aspirin)', []]], 'Rationale': 'May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3535de55931cf3ed63a'), 'Organ System, Therapeutic Category, Drug(s)': ['Anti-infective', ['Nitrofurantoin', []]], 'Rationale': 'Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available', 'Recommendation': 'Avoid in individuals with creatinine clearance <30 mL/min or for long-term suppression', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3535de55931cf3ed63b'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Peripheral alpha-1 blockers for treatment of hypertension', ['Prazosin', 'Terazosin', 'Guanabenz']]], 'Rationale': 'High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/beneﬁt proﬁle', 'Recommendation': 'Avoid use as an antihypertensive', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3535de55931cf3ed63c'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Central alpha-agonists', []]], 'Rationale': '', 'Recommendation': 'Avoid as ﬁrst-line antihypertensive', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3535de55931cf3ed63d'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Clonidine for ﬁrst-line treatment of hypertension\nOther CNS alpha-agonists', ['Guanfacine', 'Methyldopa', 'Reserpine (>0.1 mg/day)', 'Amitriptyline']]], 'Rationale': 'High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension', 'Recommendation': 'Avoid other CNS alpha-agonists as listed', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3535de55931cf3ed63e'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Disopyramide', []]], 'Rationale': 'May induce heart failure in older adults because of potent negative inotropic action; strongly anticholinergic; other antiarrhythmic drugs preferred', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3535de55931cf3ed63f'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Dronedarone', []]], 'Rationale': 'Worse outcomes have been reported in patients taking dronedarone who have permanent atrial ﬁbrillation or severe or recently decompensated heart failure.', 'Recommendation': 'Avoid in individuals with permanent atrial ﬁbrillation or severe or recently decompensated heart failure', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3535de55931cf3ed640'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Digoxin for ﬁrst-line treatment of atrial ﬁbrillation or of heart failure', []]], 'Rationale': 'Use in atrial ﬁbrillation: should not be used as ﬁrst-line agent in atrial ﬁbrillation, because there are safer and more effective alternatives for rate control supported by high-quality evidence.\nUse in heart failure: evidence for beneﬁts and harms of digoxin is conﬂicting and of lower quality; most but not all of the evidence concerns use in HFrEF. There is strong evidence for other agents as ﬁrst-line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional beneﬁt and may increase risk of toxicity.\nDecreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with stage or chronic kidney disease.', 'Recommendation': 'Avoid this rate control agent as ﬁrst- line therapy for atrial ﬁbrillation\nAvoid as ﬁrst-line therapy for heart failure\nIf used for atrial ﬁbrillation or heart failure, avoid dosages >0.125 mg/day >0.', 'Quality of Evidence': 'Atrial ﬁbrillation:', 'Strenght of Recommendation': 'Atrial ﬁbrillation:'}
{'_id': ObjectId('65cce3535de55931cf3ed641'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Nifedipine, immediate release', []]], 'Rationale': 'Potential for hypotension; risk of precipitating myocardial ischemia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3535de55931cf3ed642'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Amiodarone', []]], 'Rationale': 'Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial ﬁbrillation; may be reasonable ﬁrst-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control', 'Recommendation': 'Avoid as ﬁrst-line therapy for atrial ﬁbrillation unless patient has heart failure or substantial left ventricular hypertrophy', 'Quality of Evidence': 'Heart failure:', 'Strenght of Recommendation': 'Heart failure:'}
{'_id': ObjectId('65cce3535de55931cf3ed643'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antidepressants, alone or in combination', ['Amoxapine', 'Clomipramine', 'Desipramine', 'Doxepin >6 mg/day', 'Imipramine', 'Nortriptyline', 'Paroxetine', 'Protriptyline', 'Trimipramine', 'Amobarbital']]], 'Rationale': 'Highly anticholinergic, sedating, and cause orthostatic hypotension; safety proﬁle of low-dose doxepin (≤6 mg/day) comparable to that of placebo', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3535de55931cf3ed644'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antipsychotics, ﬁrst (conventional) and second (atypical) generation', []]], 'Rationale': 'Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia\nAvoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others', 'Recommendation': 'Avoid, except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy', 'Quality of Evidence': 'Dosage', 'Strenght of Recommendation': 'Dosage'}
{'_id': ObjectId('65cce3545de55931cf3ed645'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Barbiturates', ['Butabarbital', 'Butalbital', 'Mephobarbital', 'Pentobarbital', 'Phenobarbital', 'Secobarbital', 'Alprazolam']]], 'Rationale': 'High rate of physical dependence, tolerance to sleep beneﬁts, greater risk of overdose at low dosages', 'Recommendation': 'Avoid', 'Quality of Evidence': '>.125 mg/day:', 'Strenght of Recommendation': '>.125 mg/day:'}
{'_id': ObjectId('65cce3545de55931cf3ed646'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Benzodiazepines', ['Estazolam', 'Lorazepam', 'Oxazepam', 'Temazepam', 'Triazolam', 'Chlordiazepoxide (alone or in combination with amitriptyline or clidinium)', 'Clonazepam', 'Clorazepate', 'Diazepam', 'Flurazepam', 'Quazepam', 'Eszopiclone']]], 'Rationale': 'Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long- acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults\nMay be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'moderate', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3545de55931cf3ed647'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Meprobamate', []]], 'Rationale': 'High rate of physical dependence; sedating', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed648'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”)', ['Zaleplon', 'Zolpidem', 'Methyltestosterone']]], 'Rationale': 'Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (ie, drugs) have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/ hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed649'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Ergoloid mesylates (dehydrogenated ergot alkaloids)\nIsoxsuprine', []]], 'Rationale': 'Lack of efﬁcacy', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed64a'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Androgens', ['Testosterone', 'Chlorpropamide']]], 'Rationale': 'Potential for cardiac problems; contraindicated in men with prostate cancer', 'Recommendation': 'Avoid unless indicated for conﬁrmed hypogonadism with clinical symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed64b'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Desiccated thyroid', []]], 'Rationale': 'Concerns about cardiac effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed64c'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Estrogens with or without progestins', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid systemic estrogen (eg, oral and topical patch) nt Vaginal cream or vaginal tablets: acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed64d'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Growth hormone', []]], 'Rationale': 'Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose', 'Recommendation': 'Avoid, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deﬁciency due to an established etiology', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed64e'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Insulin, sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin)', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed64f'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Megestrol', []]], 'Rationale': 'Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed650'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Sulfonylureas, long acting', ['Glimepiride', 'Glyburide (also known as glibenclamide)', 'Aspirin >325 mg/day']]], 'Rationale': 'Chlorpropamide: prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Weak'}
{'_id': ObjectId('65cce3545de55931cf3ed651'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Metoclopramide', []]], 'Rationale': 'Glimepiride and glyburide: higher risk of severe prolonged hypoglycemia in older adults\nCan cause extrapyramidal effects, including tardive dyskinesia; risk may be greater in frail older adults and with prolonged exposure', 'Recommendation': 'Avoid, unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed652'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Mineral oil, given orally', []]], 'Rationale': 'Potential for aspiration and adverse effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Oral and patch:', 'Strenght of Recommendation': 'Oral and patch:'}
{'_id': ObjectId('65cce3545de55931cf3ed653'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Proton-pump inhibitors', []]], 'Rationale': 'Risk of Clostridium difﬁcile infection and bone loss and fractures', 'Recommendation': 'Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)', 'Quality of Evidence': 'high', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3545de55931cf3ed654'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Meperidine', []]], 'Rationale': 'Oral analgesic not effective in dosages commonly used; may have higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Vaginal cream', 'Strenght of Recommendation': 'Topical vaginal'}
{'_id': ObjectId('65cce3545de55931cf3ed655'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Non–cyclooxygenase-selective NSAIDs, oral:', ['Diclofenac', 'Diﬂunisal', 'Etodolac', 'Fenoprofen', 'Ibuprofen', 'Ketoprofen', 'Meclofenamate', 'Mefenamic acid', 'Meloxicam', 'Nabumetone', 'Naproxen', 'Oxaprozin', 'Piroxicam', 'Sulindac', 'Tolmetin', 'Carisoprodol']]], 'Rationale': 'Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for', 'Recommendation': 'Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)', 'Quality of Evidence': 'or vaginal', 'Strenght of Recommendation': 'cream or tablets:'}
{'_id': ObjectId('65cce3545de55931cf3ed656'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Indomethacin\nKetorolac, includes parenteral', []]], 'Rationale': '3-6 months and in ~2%-4% of patients treated for year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. \nRisks are dose related.\nIncreased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'tablets:', 'Strenght of Recommendation': 'weak'}
{'_id': ObjectId('65cce3545de55931cf3ed657'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Skeletal muscle relaxants', ['Chlorzoxazone', 'Cyclobenzaprine', 'Metaxalone', 'Methocarbamol', 'Orphenadrine']]], 'Rationale': 'Indomethacin is more likely than other NSAIDs to have adverse CNS effects. Of all the NSAIDs, indomethacin has the most adverse effects.\nMost muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3545de55931cf3ed658'), 'Organ System, Therapeutic Category, Drug(s)': ['Genitourinary', ['Desmopressin', []]], 'Rationale': 'High risk of hyponatremia; safer alternative treatments', 'Recommendation': 'Avoid for treatment of nocturia or nocturnal polyuria', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b4039838c3c548f3ad'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['First-generation antihistamines', ['Brompheniramine', 'Carbinoxamine', 'Chlorpheniramine', 'Clemastine', 'Cyproheptadine', 'Dexbrompheniramine', 'Dexchlorpheniramine', 'Dimenhydrinate', 'Diphenhydramine (oral)', 'Doxylamine', 'Hydroxyzine', 'Meclizine', 'Promethazine', 'Pyrilamine', 'Triprolidine']]], 'Rationale': 'Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity\nUse of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate.', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b5039838c3c548f3ae'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antiparkinsonian agents', ['Benztropine (oral)', 'Trihexyphenidyl']]], 'Rationale': 'Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b5039838c3c548f3af'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antispasmodics', ['Atropine (excludes ophthalmic)', 'Belladonna alkaloids', 'Clidinium-chlordiazepoxide', 'Dicyclomine Homatropine (excludes opthalmic)', 'Hyoscyamine', 'Methscopolamine', 'Propantheline', 'Scopolamine', 'Doxazosin']]], 'Rationale': 'Highly anticholinergic, uncertain effectiveness', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b5039838c3c548f3b0'), 'Organ System, Therapeutic Category, Drug(s)': ['Antithrombotics', ['Dipyridamole, oral short acting (does not apply to the extended-release combination with aspirin)', []]], 'Rationale': 'May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b5039838c3c548f3b1'), 'Organ System, Therapeutic Category, Drug(s)': ['Anti-infective', ['Nitrofurantoin', []]], 'Rationale': 'Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available', 'Recommendation': 'Avoid in individuals with creatinine clearance <30 mL/min or for long-term suppression', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3b2'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Peripheral alpha-1 blockers for treatment of hypertension', ['Prazosin', 'Terazosin', 'Guanabenz']]], 'Rationale': 'High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/beneﬁt proﬁle', 'Recommendation': 'Avoid use as an antihypertensive', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3b3'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Central alpha-agonists', []]], 'Rationale': '', 'Recommendation': 'Avoid as ﬁrst-line antihypertensive', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3b4'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Clonidine for ﬁrst-line treatment of hypertension\nOther CNS alpha-agonists', ['Guanfacine', 'Methyldopa', 'Reserpine (>0.1 mg/day)', 'Amitriptyline']]], 'Rationale': 'High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension', 'Recommendation': 'Avoid other CNS alpha-agonists as listed', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3b5'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Disopyramide', []]], 'Rationale': 'May induce heart failure in older adults because of potent negative inotropic action; strongly anticholinergic; other antiarrhythmic drugs preferred', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3b6'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Dronedarone', []]], 'Rationale': 'Worse outcomes have been reported in patients taking dronedarone who have permanent atrial ﬁbrillation or severe or recently decompensated heart failure.', 'Recommendation': 'Avoid in individuals with permanent atrial ﬁbrillation or severe or recently decompensated heart failure', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3b7'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Digoxin for ﬁrst-line treatment of atrial ﬁbrillation or of heart failure', []]], 'Rationale': 'Use in atrial ﬁbrillation: should not be used as ﬁrst-line agent in atrial ﬁbrillation, because there are safer and more effective alternatives for rate control supported by high-quality evidence.\nUse in heart failure: evidence for beneﬁts and harms of digoxin is conﬂicting and of lower quality; most but not all of the evidence concerns use in HFrEF. There is strong evidence for other agents as ﬁrst-line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional beneﬁt and may increase risk of toxicity.\nDecreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with stage or chronic kidney disease.', 'Recommendation': 'Avoid this rate control agent as ﬁrst- line therapy for atrial ﬁbrillation\nAvoid as ﬁrst-line therapy for heart failure\nIf used for atrial ﬁbrillation or heart failure, avoid dosages >0.125 mg/day >0.', 'Quality of Evidence': 'Atrial ﬁbrillation:', 'Strenght of Recommendation': 'Atrial ﬁbrillation:'}
{'_id': ObjectId('65cce3b6039838c3c548f3b8'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Nifedipine, immediate release', []]], 'Rationale': 'Potential for hypotension; risk of precipitating myocardial ischemia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3b9'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Amiodarone', []]], 'Rationale': 'Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial ﬁbrillation; may be reasonable ﬁrst-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control', 'Recommendation': 'Avoid as ﬁrst-line therapy for atrial ﬁbrillation unless patient has heart failure or substantial left ventricular hypertrophy', 'Quality of Evidence': 'Heart failure:', 'Strenght of Recommendation': 'Heart failure:'}
{'_id': ObjectId('65cce3b6039838c3c548f3ba'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antidepressants, alone or in combination', ['Amoxapine', 'Clomipramine', 'Desipramine', 'Doxepin >6 mg/day', 'Imipramine', 'Nortriptyline', 'Paroxetine', 'Protriptyline', 'Trimipramine', 'Amobarbital']]], 'Rationale': 'Highly anticholinergic, sedating, and cause orthostatic hypotension; safety proﬁle of low-dose doxepin (≤6 mg/day) comparable to that of placebo', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3bb'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antipsychotics, ﬁrst (conventional) and second (atypical) generation', []]], 'Rationale': 'Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia\nAvoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others', 'Recommendation': 'Avoid, except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy', 'Quality of Evidence': 'Dosage', 'Strenght of Recommendation': 'Dosage'}
{'_id': ObjectId('65cce3b6039838c3c548f3bc'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Barbiturates', ['Butabarbital', 'Butalbital', 'Mephobarbital', 'Pentobarbital', 'Phenobarbital', 'Secobarbital', 'Alprazolam']]], 'Rationale': 'High rate of physical dependence, tolerance to sleep beneﬁts, greater risk of overdose at low dosages', 'Recommendation': 'Avoid', 'Quality of Evidence': '>.125 mg/day:', 'Strenght of Recommendation': '>.125 mg/day:'}
{'_id': ObjectId('65cce3b6039838c3c548f3bd'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Benzodiazepines', ['Estazolam', 'Lorazepam', 'Oxazepam', 'Temazepam', 'Triazolam', 'Chlordiazepoxide (alone or in combination with amitriptyline or clidinium)', 'Clonazepam', 'Clorazepate', 'Diazepam', 'Flurazepam', 'Quazepam', 'Eszopiclone']]], 'Rationale': 'Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long- acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults\nMay be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'moderate', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3be'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Meprobamate', []]], 'Rationale': 'High rate of physical dependence; sedating', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3bf'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”)', ['Zaleplon', 'Zolpidem', 'Methyltestosterone']]], 'Rationale': 'Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (ie, drugs) have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/ hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3c0'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Ergoloid mesylates (dehydrogenated ergot alkaloids)\nIsoxsuprine', []]], 'Rationale': 'Lack of efﬁcacy', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3c1'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Androgens', ['Testosterone', 'Chlorpropamide']]], 'Rationale': 'Potential for cardiac problems; contraindicated in men with prostate cancer', 'Recommendation': 'Avoid unless indicated for conﬁrmed hypogonadism with clinical symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3c2'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Desiccated thyroid', []]], 'Rationale': 'Concerns about cardiac effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3c3'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Estrogens with or without progestins', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid systemic estrogen (eg, oral and topical patch) nt Vaginal cream or vaginal tablets: acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3c4'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Growth hormone', []]], 'Rationale': 'Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose', 'Recommendation': 'Avoid, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deﬁciency due to an established etiology', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3c5'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Insulin, sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin)', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3c6'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Megestrol', []]], 'Rationale': 'Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3c7'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Sulfonylureas, long acting', ['Glimepiride', 'Glyburide (also known as glibenclamide)', 'Aspirin >325 mg/day']]], 'Rationale': 'Chlorpropamide: prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Weak'}
{'_id': ObjectId('65cce3b6039838c3c548f3c8'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Metoclopramide', []]], 'Rationale': 'Glimepiride and glyburide: higher risk of severe prolonged hypoglycemia in older adults\nCan cause extrapyramidal effects, including tardive dyskinesia; risk may be greater in frail older adults and with prolonged exposure', 'Recommendation': 'Avoid, unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3c9'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Mineral oil, given orally', []]], 'Rationale': 'Potential for aspiration and adverse effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Oral and patch:', 'Strenght of Recommendation': 'Oral and patch:'}
{'_id': ObjectId('65cce3b6039838c3c548f3ca'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Proton-pump inhibitors', []]], 'Rationale': 'Risk of Clostridium difﬁcile infection and bone loss and fractures', 'Recommendation': 'Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)', 'Quality of Evidence': 'high', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3cb'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Meperidine', []]], 'Rationale': 'Oral analgesic not effective in dosages commonly used; may have higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Vaginal cream', 'Strenght of Recommendation': 'Topical vaginal'}
{'_id': ObjectId('65cce3b6039838c3c548f3cc'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Non–cyclooxygenase-selective NSAIDs, oral:', ['Diclofenac', 'Diﬂunisal', 'Etodolac', 'Fenoprofen', 'Ibuprofen', 'Ketoprofen', 'Meclofenamate', 'Mefenamic acid', 'Meloxicam', 'Nabumetone', 'Naproxen', 'Oxaprozin', 'Piroxicam', 'Sulindac', 'Tolmetin', 'Carisoprodol']]], 'Rationale': 'Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for', 'Recommendation': 'Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)', 'Quality of Evidence': 'or vaginal', 'Strenght of Recommendation': 'cream or tablets:'}
{'_id': ObjectId('65cce3b6039838c3c548f3cd'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Indomethacin\nKetorolac, includes parenteral', []]], 'Rationale': '3-6 months and in ~2%-4% of patients treated for year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. \nRisks are dose related.\nIncreased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'tablets:', 'Strenght of Recommendation': 'weak'}
{'_id': ObjectId('65cce3b6039838c3c548f3ce'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Skeletal muscle relaxants', ['Chlorzoxazone', 'Cyclobenzaprine', 'Metaxalone', 'Methocarbamol', 'Orphenadrine']]], 'Rationale': 'Indomethacin is more likely than other NSAIDs to have adverse CNS effects. Of all the NSAIDs, indomethacin has the most adverse effects.\nMost muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3b6039838c3c548f3cf'), 'Organ System, Therapeutic Category, Drug(s)': ['Genitourinary', ['Desmopressin', []]], 'Rationale': 'High risk of hyponatremia; safer alternative treatments', 'Recommendation': 'Avoid for treatment of nocturia or nocturnal polyuria', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e620c7d96731afe2a7'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['First-generation antihistamines', ['Brompheniramine', 'Carbinoxamine', 'Chlorpheniramine', 'Clemastine', 'Cyproheptadine', 'Dexbrompheniramine', 'Dexchlorpheniramine', 'Dimenhydrinate', 'Diphenhydramine (oral)', 'Doxylamine', 'Hydroxyzine', 'Meclizine', 'Promethazine', 'Pyrilamine', 'Triprolidine']]], 'Rationale': 'Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity\nUse of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate.', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e620c7d96731afe2a8'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antiparkinsonian agents', ['Benztropine (oral)', 'Trihexyphenidyl']]], 'Rationale': 'Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e620c7d96731afe2a9'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antispasmodics', ['Atropine (excludes ophthalmic)', 'Belladonna alkaloids', 'Clidinium-chlordiazepoxide', 'Dicyclomine Homatropine (excludes opthalmic)', 'Hyoscyamine', 'Methscopolamine', 'Propantheline', 'Scopolamine', 'Doxazosin']]], 'Rationale': 'Highly anticholinergic, uncertain effectiveness', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e620c7d96731afe2aa'), 'Organ System, Therapeutic Category, Drug(s)': ['Antithrombotics', ['Dipyridamole, oral short acting (does not apply to the extended-release combination with aspirin)', []]], 'Rationale': 'May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e620c7d96731afe2ab'), 'Organ System, Therapeutic Category, Drug(s)': ['Anti-infective', ['Nitrofurantoin', []]], 'Rationale': 'Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available', 'Recommendation': 'Avoid in individuals with creatinine clearance <30 mL/min or for long-term suppression', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e620c7d96731afe2ac'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Peripheral alpha-1 blockers for treatment of hypertension', ['Prazosin', 'Terazosin', 'Guanabenz']]], 'Rationale': 'High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/beneﬁt proﬁle', 'Recommendation': 'Avoid use as an antihypertensive', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e620c7d96731afe2ad'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Central alpha-agonists', []]], 'Rationale': '', 'Recommendation': 'Avoid as ﬁrst-line antihypertensive', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e620c7d96731afe2ae'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Clonidine for ﬁrst-line treatment of hypertension\nOther CNS alpha-agonists', ['Guanfacine', 'Methyldopa', 'Reserpine (>0.1 mg/day)', 'Amitriptyline']]], 'Rationale': 'High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension', 'Recommendation': 'Avoid other CNS alpha-agonists as listed', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e720c7d96731afe2af'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Disopyramide', []]], 'Rationale': 'May induce heart failure in older adults because of potent negative inotropic action; strongly anticholinergic; other antiarrhythmic drugs preferred', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e720c7d96731afe2b0'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Dronedarone', []]], 'Rationale': 'Worse outcomes have been reported in patients taking dronedarone who have permanent atrial ﬁbrillation or severe or recently decompensated heart failure.', 'Recommendation': 'Avoid in individuals with permanent atrial ﬁbrillation or severe or recently decompensated heart failure', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e720c7d96731afe2b1'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Digoxin for ﬁrst-line treatment of atrial ﬁbrillation or of heart failure', []]], 'Rationale': 'Use in atrial ﬁbrillation: should not be used as ﬁrst-line agent in atrial ﬁbrillation, because there are safer and more effective alternatives for rate control supported by high-quality evidence.\nUse in heart failure: evidence for beneﬁts and harms of digoxin is conﬂicting and of lower quality; most but not all of the evidence concerns use in HFrEF. There is strong evidence for other agents as ﬁrst-line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional beneﬁt and may increase risk of toxicity.\nDecreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with stage or chronic kidney disease.', 'Recommendation': 'Avoid this rate control agent as ﬁrst- line therapy for atrial ﬁbrillation\nAvoid as ﬁrst-line therapy for heart failure\nIf used for atrial ﬁbrillation or heart failure, avoid dosages >0.125 mg/day >0.', 'Quality of Evidence': 'Atrial ﬁbrillation:', 'Strenght of Recommendation': 'Atrial ﬁbrillation:'}
{'_id': ObjectId('65cce3e720c7d96731afe2b2'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Nifedipine, immediate release', []]], 'Rationale': 'Potential for hypotension; risk of precipitating myocardial ischemia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3e720c7d96731afe2b3'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Amiodarone', []]], 'Rationale': 'Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial ﬁbrillation; may be reasonable ﬁrst-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control', 'Recommendation': 'Avoid as ﬁrst-line therapy for atrial ﬁbrillation unless patient has heart failure or substantial left ventricular hypertrophy', 'Quality of Evidence': 'Heart failure:', 'Strenght of Recommendation': 'Heart failure:'}
{'_id': ObjectId('65cce3e720c7d96731afe2b4'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antidepressants, alone or in combination', ['Amoxapine', 'Clomipramine', 'Desipramine', 'Doxepin >6 mg/day', 'Imipramine', 'Nortriptyline', 'Paroxetine', 'Protriptyline', 'Trimipramine', 'Amobarbital']]], 'Rationale': 'Highly anticholinergic, sedating, and cause orthostatic hypotension; safety proﬁle of low-dose doxepin (≤6 mg/day) comparable to that of placebo', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3e720c7d96731afe2b5'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antipsychotics, ﬁrst (conventional) and second (atypical) generation', []]], 'Rationale': 'Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia\nAvoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others', 'Recommendation': 'Avoid, except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy', 'Quality of Evidence': 'Dosage', 'Strenght of Recommendation': 'Dosage'}
{'_id': ObjectId('65cce3e720c7d96731afe2b6'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Barbiturates', ['Butabarbital', 'Butalbital', 'Mephobarbital', 'Pentobarbital', 'Phenobarbital', 'Secobarbital', 'Alprazolam']]], 'Rationale': 'High rate of physical dependence, tolerance to sleep beneﬁts, greater risk of overdose at low dosages', 'Recommendation': 'Avoid', 'Quality of Evidence': '>.125 mg/day:', 'Strenght of Recommendation': '>.125 mg/day:'}
{'_id': ObjectId('65cce3e720c7d96731afe2b7'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Benzodiazepines', ['Estazolam', 'Lorazepam', 'Oxazepam', 'Temazepam', 'Triazolam', 'Chlordiazepoxide (alone or in combination with amitriptyline or clidinium)', 'Clonazepam', 'Clorazepate', 'Diazepam', 'Flurazepam', 'Quazepam', 'Eszopiclone']]], 'Rationale': 'Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long- acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults\nMay be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'moderate', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2b8'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Meprobamate', []]], 'Rationale': 'High rate of physical dependence; sedating', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2b9'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”)', ['Zaleplon', 'Zolpidem', 'Methyltestosterone']]], 'Rationale': 'Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (ie, drugs) have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/ hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2ba'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Ergoloid mesylates (dehydrogenated ergot alkaloids)\nIsoxsuprine', []]], 'Rationale': 'Lack of efﬁcacy', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2bb'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Androgens', ['Testosterone', 'Chlorpropamide']]], 'Rationale': 'Potential for cardiac problems; contraindicated in men with prostate cancer', 'Recommendation': 'Avoid unless indicated for conﬁrmed hypogonadism with clinical symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2bc'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Desiccated thyroid', []]], 'Rationale': 'Concerns about cardiac effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2bd'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Estrogens with or without progestins', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid systemic estrogen (eg, oral and topical patch) nt Vaginal cream or vaginal tablets: acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2be'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Growth hormone', []]], 'Rationale': 'Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose', 'Recommendation': 'Avoid, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deﬁciency due to an established etiology', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2bf'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Insulin, sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin)', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2c0'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Megestrol', []]], 'Rationale': 'Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2c1'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Sulfonylureas, long acting', ['Glimepiride', 'Glyburide (also known as glibenclamide)', 'Aspirin >325 mg/day']]], 'Rationale': 'Chlorpropamide: prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Weak'}
{'_id': ObjectId('65cce3e820c7d96731afe2c2'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Metoclopramide', []]], 'Rationale': 'Glimepiride and glyburide: higher risk of severe prolonged hypoglycemia in older adults\nCan cause extrapyramidal effects, including tardive dyskinesia; risk may be greater in frail older adults and with prolonged exposure', 'Recommendation': 'Avoid, unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2c3'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Mineral oil, given orally', []]], 'Rationale': 'Potential for aspiration and adverse effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Oral and patch:', 'Strenght of Recommendation': 'Oral and patch:'}
{'_id': ObjectId('65cce3e820c7d96731afe2c4'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Proton-pump inhibitors', []]], 'Rationale': 'Risk of Clostridium difﬁcile infection and bone loss and fractures', 'Recommendation': 'Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)', 'Quality of Evidence': 'high', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2c5'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Meperidine', []]], 'Rationale': 'Oral analgesic not effective in dosages commonly used; may have higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Vaginal cream', 'Strenght of Recommendation': 'Topical vaginal'}
{'_id': ObjectId('65cce3e820c7d96731afe2c6'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Non–cyclooxygenase-selective NSAIDs, oral:', ['Diclofenac', 'Diﬂunisal', 'Etodolac', 'Fenoprofen', 'Ibuprofen', 'Ketoprofen', 'Meclofenamate', 'Mefenamic acid', 'Meloxicam', 'Nabumetone', 'Naproxen', 'Oxaprozin', 'Piroxicam', 'Sulindac', 'Tolmetin', 'Carisoprodol']]], 'Rationale': 'Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for', 'Recommendation': 'Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)', 'Quality of Evidence': 'or vaginal', 'Strenght of Recommendation': 'cream or tablets:'}
{'_id': ObjectId('65cce3e820c7d96731afe2c7'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Indomethacin\nKetorolac, includes parenteral', []]], 'Rationale': '3-6 months and in ~2%-4% of patients treated for year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. \nRisks are dose related.\nIncreased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'tablets:', 'Strenght of Recommendation': 'weak'}
{'_id': ObjectId('65cce3e820c7d96731afe2c8'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Skeletal muscle relaxants', ['Chlorzoxazone', 'Cyclobenzaprine', 'Metaxalone', 'Methocarbamol', 'Orphenadrine']]], 'Rationale': 'Indomethacin is more likely than other NSAIDs to have adverse CNS effects. Of all the NSAIDs, indomethacin has the most adverse effects.\nMost muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce3e820c7d96731afe2c9'), 'Organ System, Therapeutic Category, Drug(s)': ['Genitourinary', ['Desmopressin', []]], 'Rationale': 'High risk of hyponatremia; safer alternative treatments', 'Recommendation': 'Avoid for treatment of nocturia or nocturnal polyuria', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce42eccac68b55800cfc5'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['First-generation antihistamines', ['Brompheniramine', 'Carbinoxamine', 'Chlorpheniramine', 'Clemastine', 'Cyproheptadine', 'Dexbrompheniramine', 'Dexchlorpheniramine', 'Dimenhydrinate', 'Diphenhydramine (oral)', 'Doxylamine', 'Hydroxyzine', 'Meclizine', 'Promethazine', 'Pyrilamine', 'Triprolidine']]], 'Rationale': 'Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity\nUse of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate.', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce42fccac68b55800cfc6'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antiparkinsonian agents', ['Benztropine (oral)', 'Trihexyphenidyl']]], 'Rationale': 'Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce42fccac68b55800cfc7'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antispasmodics', ['Atropine (excludes ophthalmic)', 'Belladonna alkaloids', 'Clidinium-chlordiazepoxide', 'Dicyclomine Homatropine (excludes opthalmic)', 'Hyoscyamine', 'Methscopolamine', 'Propantheline', 'Scopolamine', 'Doxazosin']]], 'Rationale': 'Highly anticholinergic, uncertain effectiveness', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce42fccac68b55800cfc8'), 'Organ System, Therapeutic Category, Drug(s)': ['Antithrombotics', ['Dipyridamole, oral short acting (does not apply to the extended-release combination with aspirin)', []]], 'Rationale': 'May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce42fccac68b55800cfc9'), 'Organ System, Therapeutic Category, Drug(s)': ['Anti-infective', ['Nitrofurantoin', []]], 'Rationale': 'Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available', 'Recommendation': 'Avoid in individuals with creatinine clearance <30 mL/min or for long-term suppression', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce42fccac68b55800cfca'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Peripheral alpha-1 blockers for treatment of hypertension', ['Prazosin', 'Terazosin', 'Guanabenz']]], 'Rationale': 'High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/beneﬁt proﬁle', 'Recommendation': 'Avoid use as an antihypertensive', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce42fccac68b55800cfcb'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Central alpha-agonists', []]], 'Rationale': '', 'Recommendation': 'Avoid as ﬁrst-line antihypertensive', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce42fccac68b55800cfcc'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Clonidine for ﬁrst-line treatment of hypertension\nOther CNS alpha-agonists', ['Guanfacine', 'Methyldopa', 'Reserpine (>0.1 mg/day)', 'Amitriptyline']]], 'Rationale': 'High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension', 'Recommendation': 'Avoid other CNS alpha-agonists as listed', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce42fccac68b55800cfcd'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Disopyramide', []]], 'Rationale': 'May induce heart failure in older adults because of potent negative inotropic action; strongly anticholinergic; other antiarrhythmic drugs preferred', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfce'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Dronedarone', []]], 'Rationale': 'Worse outcomes have been reported in patients taking dronedarone who have permanent atrial ﬁbrillation or severe or recently decompensated heart failure.', 'Recommendation': 'Avoid in individuals with permanent atrial ﬁbrillation or severe or recently decompensated heart failure', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfcf'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Digoxin for ﬁrst-line treatment of atrial ﬁbrillation or of heart failure', []]], 'Rationale': 'Use in atrial ﬁbrillation: should not be used as ﬁrst-line agent in atrial ﬁbrillation, because there are safer and more effective alternatives for rate control supported by high-quality evidence.\nUse in heart failure: evidence for beneﬁts and harms of digoxin is conﬂicting and of lower quality; most but not all of the evidence concerns use in HFrEF. There is strong evidence for other agents as ﬁrst-line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional beneﬁt and may increase risk of toxicity.\nDecreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with stage or chronic kidney disease.', 'Recommendation': 'Avoid this rate control agent as ﬁrst- line therapy for atrial ﬁbrillation\nAvoid as ﬁrst-line therapy for heart failure\nIf used for atrial ﬁbrillation or heart failure, avoid dosages >0.125 mg/day >0.', 'Quality of Evidence': 'Atrial ﬁbrillation:', 'Strenght of Recommendation': 'Atrial ﬁbrillation:'}
{'_id': ObjectId('65cce430ccac68b55800cfd0'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Nifedipine, immediate release', []]], 'Rationale': 'Potential for hypotension; risk of precipitating myocardial ischemia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce430ccac68b55800cfd1'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Amiodarone', []]], 'Rationale': 'Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial ﬁbrillation; may be reasonable ﬁrst-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control', 'Recommendation': 'Avoid as ﬁrst-line therapy for atrial ﬁbrillation unless patient has heart failure or substantial left ventricular hypertrophy', 'Quality of Evidence': 'Heart failure:', 'Strenght of Recommendation': 'Heart failure:'}
{'_id': ObjectId('65cce430ccac68b55800cfd2'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antidepressants, alone or in combination', ['Amoxapine', 'Clomipramine', 'Desipramine', 'Doxepin >6 mg/day', 'Imipramine', 'Nortriptyline', 'Paroxetine', 'Protriptyline', 'Trimipramine', 'Amobarbital']]], 'Rationale': 'Highly anticholinergic, sedating, and cause orthostatic hypotension; safety proﬁle of low-dose doxepin (≤6 mg/day) comparable to that of placebo', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce430ccac68b55800cfd3'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antipsychotics, ﬁrst (conventional) and second (atypical) generation', []]], 'Rationale': 'Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia\nAvoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others', 'Recommendation': 'Avoid, except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy', 'Quality of Evidence': 'Dosage', 'Strenght of Recommendation': 'Dosage'}
{'_id': ObjectId('65cce430ccac68b55800cfd4'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Barbiturates', ['Butabarbital', 'Butalbital', 'Mephobarbital', 'Pentobarbital', 'Phenobarbital', 'Secobarbital', 'Alprazolam']]], 'Rationale': 'High rate of physical dependence, tolerance to sleep beneﬁts, greater risk of overdose at low dosages', 'Recommendation': 'Avoid', 'Quality of Evidence': '>.125 mg/day:', 'Strenght of Recommendation': '>.125 mg/day:'}
{'_id': ObjectId('65cce430ccac68b55800cfd5'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Benzodiazepines', ['Estazolam', 'Lorazepam', 'Oxazepam', 'Temazepam', 'Triazolam', 'Chlordiazepoxide (alone or in combination with amitriptyline or clidinium)', 'Clonazepam', 'Clorazepate', 'Diazepam', 'Flurazepam', 'Quazepam', 'Eszopiclone']]], 'Rationale': 'Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long- acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults\nMay be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'moderate', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce430ccac68b55800cfd6'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Meprobamate', []]], 'Rationale': 'High rate of physical dependence; sedating', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfd7'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”)', ['Zaleplon', 'Zolpidem', 'Methyltestosterone']]], 'Rationale': 'Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (ie, drugs) have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/ hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfd8'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Ergoloid mesylates (dehydrogenated ergot alkaloids)\nIsoxsuprine', []]], 'Rationale': 'Lack of efﬁcacy', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfd9'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Androgens', ['Testosterone', 'Chlorpropamide']]], 'Rationale': 'Potential for cardiac problems; contraindicated in men with prostate cancer', 'Recommendation': 'Avoid unless indicated for conﬁrmed hypogonadism with clinical symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfda'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Desiccated thyroid', []]], 'Rationale': 'Concerns about cardiac effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfdb'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Estrogens with or without progestins', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid systemic estrogen (eg, oral and topical patch) nt Vaginal cream or vaginal tablets: acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfdc'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Growth hormone', []]], 'Rationale': 'Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose', 'Recommendation': 'Avoid, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deﬁciency due to an established etiology', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfdd'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Insulin, sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin)', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfde'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Megestrol', []]], 'Rationale': 'Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfdf'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Sulfonylureas, long acting', ['Glimepiride', 'Glyburide (also known as glibenclamide)', 'Aspirin >325 mg/day']]], 'Rationale': 'Chlorpropamide: prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Weak'}
{'_id': ObjectId('65cce430ccac68b55800cfe0'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Metoclopramide', []]], 'Rationale': 'Glimepiride and glyburide: higher risk of severe prolonged hypoglycemia in older adults\nCan cause extrapyramidal effects, including tardive dyskinesia; risk may be greater in frail older adults and with prolonged exposure', 'Recommendation': 'Avoid, unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfe1'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Mineral oil, given orally', []]], 'Rationale': 'Potential for aspiration and adverse effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Oral and patch:', 'Strenght of Recommendation': 'Oral and patch:'}
{'_id': ObjectId('65cce430ccac68b55800cfe2'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Proton-pump inhibitors', []]], 'Rationale': 'Risk of Clostridium difﬁcile infection and bone loss and fractures', 'Recommendation': 'Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)', 'Quality of Evidence': 'high', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce430ccac68b55800cfe3'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Meperidine', []]], 'Rationale': 'Oral analgesic not effective in dosages commonly used; may have higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Vaginal cream', 'Strenght of Recommendation': 'Topical vaginal'}
{'_id': ObjectId('65cce430ccac68b55800cfe4'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Non–cyclooxygenase-selective NSAIDs, oral:', ['Diclofenac', 'Diﬂunisal', 'Etodolac', 'Fenoprofen', 'Ibuprofen', 'Ketoprofen', 'Meclofenamate', 'Mefenamic acid', 'Meloxicam', 'Nabumetone', 'Naproxen', 'Oxaprozin', 'Piroxicam', 'Sulindac', 'Tolmetin', 'Carisoprodol']]], 'Rationale': 'Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for', 'Recommendation': 'Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)', 'Quality of Evidence': 'or vaginal', 'Strenght of Recommendation': 'cream or tablets:'}
{'_id': ObjectId('65cce430ccac68b55800cfe5'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Indomethacin\nKetorolac, includes parenteral', []]], 'Rationale': '3-6 months and in ~2%-4% of patients treated for year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. \nRisks are dose related.\nIncreased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'tablets:', 'Strenght of Recommendation': 'weak'}
{'_id': ObjectId('65cce430ccac68b55800cfe6'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Skeletal muscle relaxants', ['Chlorzoxazone', 'Cyclobenzaprine', 'Metaxalone', 'Methocarbamol', 'Orphenadrine']]], 'Rationale': 'Indomethacin is more likely than other NSAIDs to have adverse CNS effects. Of all the NSAIDs, indomethacin has the most adverse effects.\nMost muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce430ccac68b55800cfe7'), 'Organ System, Therapeutic Category, Drug(s)': ['Genitourinary', ['Desmopressin', []]], 'Rationale': 'High risk of hyponatremia; safer alternative treatments', 'Recommendation': 'Avoid for treatment of nocturia or nocturnal polyuria', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5045a123cb5b78fff70'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['First-generation antihistamines', ['Brompheniramine', 'Carbinoxamine', 'Chlorpheniramine', 'Clemastine', 'Cyproheptadine', 'Dexbrompheniramine', 'Dexchlorpheniramine', 'Dimenhydrinate', 'Diphenhydramine (oral)', 'Doxylamine', 'Hydroxyzine', 'Meclizine', 'Promethazine', 'Pyrilamine', 'Triprolidine']]], 'Rationale': 'Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity\nUse of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate.', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff71'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antiparkinsonian agents', ['Benztropine (oral)', 'Trihexyphenidyl']]], 'Rationale': 'Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff72'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antispasmodics', ['Atropine (excludes ophthalmic)', 'Belladonna alkaloids', 'Clidinium-chlordiazepoxide', 'Dicyclomine Homatropine (excludes opthalmic)', 'Hyoscyamine', 'Methscopolamine', 'Propantheline', 'Scopolamine', 'Doxazosin']]], 'Rationale': 'Highly anticholinergic, uncertain effectiveness', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff73'), 'Organ System, Therapeutic Category, Drug(s)': ['Antithrombotics', ['Dipyridamole, oral short acting (does not apply to the extended-release combination with aspirin)', []]], 'Rationale': 'May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff74'), 'Organ System, Therapeutic Category, Drug(s)': ['Anti-infective', ['Nitrofurantoin', []]], 'Rationale': 'Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available', 'Recommendation': 'Avoid in individuals with creatinine clearance <30 mL/min or for long-term suppression', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff75'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Peripheral alpha-1 blockers for treatment of hypertension', ['Prazosin', 'Terazosin', 'Guanabenz']]], 'Rationale': 'High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/beneﬁt proﬁle', 'Recommendation': 'Avoid use as an antihypertensive', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff76'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Central alpha-agonists', []]], 'Rationale': '', 'Recommendation': 'Avoid as ﬁrst-line antihypertensive', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff77'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Clonidine for ﬁrst-line treatment of hypertension\nOther CNS alpha-agonists', ['Guanfacine', 'Methyldopa', 'Reserpine (>0.1 mg/day)', 'Amitriptyline']]], 'Rationale': 'High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension', 'Recommendation': 'Avoid other CNS alpha-agonists as listed', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff78'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Disopyramide', []]], 'Rationale': 'May induce heart failure in older adults because of potent negative inotropic action; strongly anticholinergic; other antiarrhythmic drugs preferred', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff79'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Dronedarone', []]], 'Rationale': 'Worse outcomes have been reported in patients taking dronedarone who have permanent atrial ﬁbrillation or severe or recently decompensated heart failure.', 'Recommendation': 'Avoid in individuals with permanent atrial ﬁbrillation or severe or recently decompensated heart failure', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff7a'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Digoxin for ﬁrst-line treatment of atrial ﬁbrillation or of heart failure', []]], 'Rationale': 'Use in atrial ﬁbrillation: should not be used as ﬁrst-line agent in atrial ﬁbrillation, because there are safer and more effective alternatives for rate control supported by high-quality evidence.\nUse in heart failure: evidence for beneﬁts and harms of digoxin is conﬂicting and of lower quality; most but not all of the evidence concerns use in HFrEF. There is strong evidence for other agents as ﬁrst-line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional beneﬁt and may increase risk of toxicity.\nDecreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with stage or chronic kidney disease.', 'Recommendation': 'Avoid this rate control agent as ﬁrst- line therapy for atrial ﬁbrillation\nAvoid as ﬁrst-line therapy for heart failure\nIf used for atrial ﬁbrillation or heart failure, avoid dosages >0.125 mg/day >0.', 'Quality of Evidence': 'Atrial ﬁbrillation:', 'Strenght of Recommendation': 'Atrial ﬁbrillation:'}
{'_id': ObjectId('65cce5055a123cb5b78fff7b'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Nifedipine, immediate release', []]], 'Rationale': 'Potential for hypotension; risk of precipitating myocardial ischemia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff7c'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Amiodarone', []]], 'Rationale': 'Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial ﬁbrillation; may be reasonable ﬁrst-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control', 'Recommendation': 'Avoid as ﬁrst-line therapy for atrial ﬁbrillation unless patient has heart failure or substantial left ventricular hypertrophy', 'Quality of Evidence': 'Heart failure:', 'Strenght of Recommendation': 'Heart failure:'}
{'_id': ObjectId('65cce5055a123cb5b78fff7d'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antidepressants, alone or in combination', ['Amoxapine', 'Clomipramine', 'Desipramine', 'Doxepin >6 mg/day', 'Imipramine', 'Nortriptyline', 'Paroxetine', 'Protriptyline', 'Trimipramine', 'Amobarbital']]], 'Rationale': 'Highly anticholinergic, sedating, and cause orthostatic hypotension; safety proﬁle of low-dose doxepin (≤6 mg/day) comparable to that of placebo', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff7e'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antipsychotics, ﬁrst (conventional) and second (atypical) generation', []]], 'Rationale': 'Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia\nAvoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others', 'Recommendation': 'Avoid, except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy', 'Quality of Evidence': 'Dosage', 'Strenght of Recommendation': 'Dosage'}
{'_id': ObjectId('65cce5055a123cb5b78fff7f'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Barbiturates', ['Butabarbital', 'Butalbital', 'Mephobarbital', 'Pentobarbital', 'Phenobarbital', 'Secobarbital', 'Alprazolam']]], 'Rationale': 'High rate of physical dependence, tolerance to sleep beneﬁts, greater risk of overdose at low dosages', 'Recommendation': 'Avoid', 'Quality of Evidence': '>.125 mg/day:', 'Strenght of Recommendation': '>.125 mg/day:'}
{'_id': ObjectId('65cce5055a123cb5b78fff80'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Benzodiazepines', ['Estazolam', 'Lorazepam', 'Oxazepam', 'Temazepam', 'Triazolam', 'Chlordiazepoxide (alone or in combination with amitriptyline or clidinium)', 'Clonazepam', 'Clorazepate', 'Diazepam', 'Flurazepam', 'Quazepam', 'Eszopiclone']]], 'Rationale': 'Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long- acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults\nMay be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'moderate', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff81'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Meprobamate', []]], 'Rationale': 'High rate of physical dependence; sedating', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff82'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”)', ['Zaleplon', 'Zolpidem', 'Methyltestosterone']]], 'Rationale': 'Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (ie, drugs) have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/ hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff83'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Ergoloid mesylates (dehydrogenated ergot alkaloids)\nIsoxsuprine', []]], 'Rationale': 'Lack of efﬁcacy', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff84'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Androgens', ['Testosterone', 'Chlorpropamide']]], 'Rationale': 'Potential for cardiac problems; contraindicated in men with prostate cancer', 'Recommendation': 'Avoid unless indicated for conﬁrmed hypogonadism with clinical symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff85'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Desiccated thyroid', []]], 'Rationale': 'Concerns about cardiac effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff86'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Estrogens with or without progestins', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid systemic estrogen (eg, oral and topical patch) nt Vaginal cream or vaginal tablets: acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff87'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Growth hormone', []]], 'Rationale': 'Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose', 'Recommendation': 'Avoid, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deﬁciency due to an established etiology', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff88'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Insulin, sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin)', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff89'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Megestrol', []]], 'Rationale': 'Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff8a'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Sulfonylureas, long acting', ['Glimepiride', 'Glyburide (also known as glibenclamide)', 'Aspirin >325 mg/day']]], 'Rationale': 'Chlorpropamide: prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Weak'}
{'_id': ObjectId('65cce5055a123cb5b78fff8b'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Metoclopramide', []]], 'Rationale': 'Glimepiride and glyburide: higher risk of severe prolonged hypoglycemia in older adults\nCan cause extrapyramidal effects, including tardive dyskinesia; risk may be greater in frail older adults and with prolonged exposure', 'Recommendation': 'Avoid, unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff8c'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Mineral oil, given orally', []]], 'Rationale': 'Potential for aspiration and adverse effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Oral and patch:', 'Strenght of Recommendation': 'Oral and patch:'}
{'_id': ObjectId('65cce5055a123cb5b78fff8d'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Proton-pump inhibitors', []]], 'Rationale': 'Risk of Clostridium difﬁcile infection and bone loss and fractures', 'Recommendation': 'Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)', 'Quality of Evidence': 'high', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce5055a123cb5b78fff8e'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Meperidine', []]], 'Rationale': 'Oral analgesic not effective in dosages commonly used; may have higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Vaginal cream', 'Strenght of Recommendation': 'Topical vaginal'}
{'_id': ObjectId('65cce5055a123cb5b78fff8f'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Non–cyclooxygenase-selective NSAIDs, oral:', ['Diclofenac', 'Diﬂunisal', 'Etodolac', 'Fenoprofen', 'Ibuprofen', 'Ketoprofen', 'Meclofenamate', 'Mefenamic acid', 'Meloxicam', 'Nabumetone', 'Naproxen', 'Oxaprozin', 'Piroxicam', 'Sulindac', 'Tolmetin', 'Carisoprodol']]], 'Rationale': 'Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for', 'Recommendation': 'Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)', 'Quality of Evidence': 'or vaginal', 'Strenght of Recommendation': 'cream or tablets:'}
{'_id': ObjectId('65cce5055a123cb5b78fff90'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Indomethacin\nKetorolac, includes parenteral', []]], 'Rationale': '3-6 months and in ~2%-4% of patients treated for year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. \nRisks are dose related.\nIncreased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'tablets:', 'Strenght of Recommendation': 'weak'}
{'_id': ObjectId('65cce5055a123cb5b78fff91'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Skeletal muscle relaxants', ['Chlorzoxazone', 'Cyclobenzaprine', 'Metaxalone', 'Methocarbamol', 'Orphenadrine']]], 'Rationale': 'Indomethacin is more likely than other NSAIDs to have adverse CNS effects. Of all the NSAIDs, indomethacin has the most adverse effects.\nMost muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce5065a123cb5b78fff92'), 'Organ System, Therapeutic Category, Drug(s)': ['Genitourinary', ['Desmopressin', []]], 'Rationale': 'High risk of hyponatremia; safer alternative treatments', 'Recommendation': 'Avoid for treatment of nocturia or nocturnal polyuria', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52e16de1163e69b7e6d'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['First-generation antihistamines', ['Brompheniramine', 'Carbinoxamine', 'Chlorpheniramine', 'Clemastine', 'Cyproheptadine', 'Dexbrompheniramine', 'Dexchlorpheniramine', 'Dimenhydrinate', 'Diphenhydramine (oral)', 'Doxylamine', 'Hydroxyzine', 'Meclizine', 'Promethazine', 'Pyrilamine', 'Triprolidine']]], 'Rationale': 'Highly anticholinergic; clearance reduced with advanced age, and tolerance develops when used as hypnotic; risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity\nUse of diphenhydramine in situations such as acute treatment of severe allergic reaction may be appropriate.', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52e16de1163e69b7e6e'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antiparkinsonian agents', ['Benztropine (oral)', 'Trihexyphenidyl']]], 'Rationale': 'Not recommended for prevention or treatment of extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e6f'), 'Organ System, Therapeutic Category, Drug(s)': ['Anticholinergics', ['Antispasmodics', ['Atropine (excludes ophthalmic)', 'Belladonna alkaloids', 'Clidinium-chlordiazepoxide', 'Dicyclomine Homatropine (excludes opthalmic)', 'Hyoscyamine', 'Methscopolamine', 'Propantheline', 'Scopolamine', 'Doxazosin']]], 'Rationale': 'Highly anticholinergic, uncertain effectiveness', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e70'), 'Organ System, Therapeutic Category, Drug(s)': ['Antithrombotics', ['Dipyridamole, oral short acting (does not apply to the extended-release combination with aspirin)', []]], 'Rationale': 'May cause orthostatic hypotension; more effective alternatives available; IV form acceptable for use in cardiac stress testing', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e71'), 'Organ System, Therapeutic Category, Drug(s)': ['Anti-infective', ['Nitrofurantoin', []]], 'Rationale': 'Potential for pulmonary toxicity, hepatoxicity, and peripheral neuropathy, especially with long-term use; safer alternatives available', 'Recommendation': 'Avoid in individuals with creatinine clearance <30 mL/min or for long-term suppression', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e72'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Peripheral alpha-1 blockers for treatment of hypertension', ['Prazosin', 'Terazosin', 'Guanabenz']]], 'Rationale': 'High risk of orthostatic hypotension and associated harms, especially in older adults; not recommended as routine treatment for hypertension; alternative agents have superior risk/beneﬁt proﬁle', 'Recommendation': 'Avoid use as an antihypertensive', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e73'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Central alpha-agonists', []]], 'Rationale': '', 'Recommendation': 'Avoid as ﬁrst-line antihypertensive', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e74'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Clonidine for ﬁrst-line treatment of hypertension\nOther CNS alpha-agonists', ['Guanfacine', 'Methyldopa', 'Reserpine (>0.1 mg/day)', 'Amitriptyline']]], 'Rationale': 'High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension', 'Recommendation': 'Avoid other CNS alpha-agonists as listed', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e75'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Disopyramide', []]], 'Rationale': 'May induce heart failure in older adults because of potent negative inotropic action; strongly anticholinergic; other antiarrhythmic drugs preferred', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e76'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Dronedarone', []]], 'Rationale': 'Worse outcomes have been reported in patients taking dronedarone who have permanent atrial ﬁbrillation or severe or recently decompensated heart failure.', 'Recommendation': 'Avoid in individuals with permanent atrial ﬁbrillation or severe or recently decompensated heart failure', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e77'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Digoxin for ﬁrst-line treatment of atrial ﬁbrillation or of heart failure', []]], 'Rationale': 'Use in atrial ﬁbrillation: should not be used as ﬁrst-line agent in atrial ﬁbrillation, because there are safer and more effective alternatives for rate control supported by high-quality evidence.\nUse in heart failure: evidence for beneﬁts and harms of digoxin is conﬂicting and of lower quality; most but not all of the evidence concerns use in HFrEF. There is strong evidence for other agents as ﬁrst-line therapy to reduce hospitalizations and mortality in adults with HFrEF. In heart failure, higher dosages are not associated with additional beneﬁt and may increase risk of toxicity.\nDecreased renal clearance of digoxin may lead to increased risk of toxic effects; further dose reduction may be necessary in those with stage or chronic kidney disease.', 'Recommendation': 'Avoid this rate control agent as ﬁrst- line therapy for atrial ﬁbrillation\nAvoid as ﬁrst-line therapy for heart failure\nIf used for atrial ﬁbrillation or heart failure, avoid dosages >0.125 mg/day >0.', 'Quality of Evidence': 'Atrial ﬁbrillation:', 'Strenght of Recommendation': 'Atrial ﬁbrillation:'}
{'_id': ObjectId('65cce52f16de1163e69b7e78'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Nifedipine, immediate release', []]], 'Rationale': 'Potential for hypotension; risk of precipitating myocardial ischemia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e79'), 'Organ System, Therapeutic Category, Drug(s)': ['Cardiovascular', ['Amiodarone', []]], 'Rationale': 'Effective for maintaining sinus rhythm but has greater toxicities than other antiarrhythmics used in atrial ﬁbrillation; may be reasonable ﬁrst-line therapy in patients with concomitant heart failure or substantial left ventricular hypertrophy if rhythm control is preferred over rate control', 'Recommendation': 'Avoid as ﬁrst-line therapy for atrial ﬁbrillation unless patient has heart failure or substantial left ventricular hypertrophy', 'Quality of Evidence': 'Heart failure:', 'Strenght of Recommendation': 'Heart failure:'}
{'_id': ObjectId('65cce52f16de1163e69b7e7a'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antidepressants, alone or in combination', ['Amoxapine', 'Clomipramine', 'Desipramine', 'Doxepin >6 mg/day', 'Imipramine', 'Nortriptyline', 'Paroxetine', 'Protriptyline', 'Trimipramine', 'Amobarbital']]], 'Rationale': 'Highly anticholinergic, sedating, and cause orthostatic hypotension; safety proﬁle of low-dose doxepin (≤6 mg/day) comparable to that of placebo', 'Recommendation': 'Avoid', 'Quality of Evidence': 'low', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e7b'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Antipsychotics, ﬁrst (conventional) and second (atypical) generation', []]], 'Rationale': 'Increased risk of cerebrovascular accident (stroke) and greater rate of cognitive decline and mortality in persons with dementia\nAvoid antipsychotics for behavioral problems of dementia or delirium unless nonpharmacological options (eg, behavioral interventions) have failed or are not possible and the older adult is threatening substantial harm to self or others', 'Recommendation': 'Avoid, except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy', 'Quality of Evidence': 'Dosage', 'Strenght of Recommendation': 'Dosage'}
{'_id': ObjectId('65cce52f16de1163e69b7e7c'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Barbiturates', ['Butabarbital', 'Butalbital', 'Mephobarbital', 'Pentobarbital', 'Phenobarbital', 'Secobarbital', 'Alprazolam']]], 'Rationale': 'High rate of physical dependence, tolerance to sleep beneﬁts, greater risk of overdose at low dosages', 'Recommendation': 'Avoid', 'Quality of Evidence': '>.125 mg/day:', 'Strenght of Recommendation': '>.125 mg/day:'}
{'_id': ObjectId('65cce52f16de1163e69b7e7d'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Benzodiazepines', ['Estazolam', 'Lorazepam', 'Oxazepam', 'Temazepam', 'Triazolam', 'Chlordiazepoxide (alone or in combination with amitriptyline or clidinium)', 'Clonazepam', 'Clorazepate', 'Diazepam', 'Flurazepam', 'Quazepam', 'Eszopiclone']]], 'Rationale': 'Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long- acting agents; in general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults\nMay be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia', 'Recommendation': 'Avoid', 'Quality of Evidence': 'moderate', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e7e'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Meprobamate', []]], 'Rationale': 'High rate of physical dependence; sedating', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e7f'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Nonbenzodiazepine, benzodiazepine receptor agonist hypnotics (ie, “Z-drugs”)', ['Zaleplon', 'Zolpidem', 'Methyltestosterone']]], 'Rationale': 'Nonbenzodiazepine benzodiazepine receptor agonist hypnotics (ie, drugs) have adverse events similar to those of benzodiazepines in older adults (eg, delirium, falls, fractures); increased emergency room visits/ hospitalizations; motor vehicle crashes; minimal improvement in sleep latency and duration', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e80'), 'Organ System, Therapeutic Category, Drug(s)': ['Central nervous system', ['Ergoloid mesylates (dehydrogenated ergot alkaloids)\nIsoxsuprine', []]], 'Rationale': 'Lack of efﬁcacy', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e81'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Androgens', ['Testosterone', 'Chlorpropamide']]], 'Rationale': 'Potential for cardiac problems; contraindicated in men with prostate cancer', 'Recommendation': 'Avoid unless indicated for conﬁrmed hypogonadism with clinical symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e82'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Desiccated thyroid', []]], 'Rationale': 'Concerns about cardiac effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e83'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Estrogens with or without progestins', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid systemic estrogen (eg, oral and topical patch) nt Vaginal cream or vaginal tablets: acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower urinary tract infections, and other vaginal symptoms', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e84'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Growth hormone', []]], 'Rationale': 'Impact on body composition is small and associated with edema, arthralgia, carpal tunnel syndrome, gynecomastia, impaired fasting glucose', 'Recommendation': 'Avoid, except for patients rigorously diagnosed by evidence-based criteria with growth hormone deﬁciency due to an established etiology', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e85'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Insulin, sliding scale (insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin)', []]], 'Rationale': 'Evidence of carcinogenic potential (breast and endometrium); lack of cardioprotective effect and cognitive protection in older women\nEvidence indicates that vaginal estrogens for the treatmen of vaginal dryness are safe and effective; women with history of breast cancer who do not respond to nonhormonal therapies are advised to discuss the risks and beneﬁts of low-dose vaginal estrogen (dosages of estradiol <25 μg twice weekly) with their healthcare provider', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e86'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Megestrol', []]], 'Rationale': 'Minimal effect on weight; increases risk of thrombotic events and possibly death in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e87'), 'Organ System, Therapeutic Category, Drug(s)': ['Endocrine', ['Sulfonylureas, long acting', ['Glimepiride', 'Glyburide (also known as glibenclamide)', 'Aspirin >325 mg/day']]], 'Rationale': 'Chlorpropamide: prolonged half-life in older adults; can cause prolonged hypoglycemia; causes SIADH', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Weak'}
{'_id': ObjectId('65cce52f16de1163e69b7e88'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Metoclopramide', []]], 'Rationale': 'Glimepiride and glyburide: higher risk of severe prolonged hypoglycemia in older adults\nCan cause extrapyramidal effects, including tardive dyskinesia; risk may be greater in frail older adults and with prolonged exposure', 'Recommendation': 'Avoid, unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases', 'Quality of Evidence': 'Low', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e89'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Mineral oil, given orally', []]], 'Rationale': 'Potential for aspiration and adverse effects; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Oral and patch:', 'Strenght of Recommendation': 'Oral and patch:'}
{'_id': ObjectId('65cce52f16de1163e69b7e8a'), 'Organ System, Therapeutic Category, Drug(s)': ['Gastrointestinal', ['Proton-pump inhibitors', []]], 'Rationale': 'Risk of Clostridium difﬁcile infection and bone loss and fractures', 'Recommendation': 'Avoid scheduled use for >8 weeks unless for high-risk patients (eg, oral corticosteroids or chronic NSAID use), erosive esophagitis, Barrett esophagitis, pathological hypersecretory condition, or demonstrated need for maintenance treatment (eg, because of failure of drug discontinuation trial or H2-receptor antagonists)', 'Quality of Evidence': 'high', 'Strenght of Recommendation': 'strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e8b'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Meperidine', []]], 'Rationale': 'Oral analgesic not effective in dosages commonly used; may have higher risk of neurotoxicity, including delirium, than other opioids; safer alternatives available', 'Recommendation': 'Avoid', 'Quality of Evidence': 'Vaginal cream', 'Strenght of Recommendation': 'Topical vaginal'}
{'_id': ObjectId('65cce52f16de1163e69b7e8c'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Non–cyclooxygenase-selective NSAIDs, oral:', ['Diclofenac', 'Diﬂunisal', 'Etodolac', 'Fenoprofen', 'Ibuprofen', 'Ketoprofen', 'Meclofenamate', 'Mefenamic acid', 'Meloxicam', 'Nabumetone', 'Naproxen', 'Oxaprozin', 'Piroxicam', 'Sulindac', 'Tolmetin', 'Carisoprodol']]], 'Rationale': 'Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75 years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents; use of proton-pump inhibitor or misoprostol reduces but does not eliminate risk. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs occur in ~1% of patients treated for', 'Recommendation': 'Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent (proton-pump inhibitor or misoprostol)', 'Quality of Evidence': 'or vaginal', 'Strenght of Recommendation': 'cream or tablets:'}
{'_id': ObjectId('65cce52f16de1163e69b7e8d'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Indomethacin\nKetorolac, includes parenteral', []]], 'Rationale': '3-6 months and in ~2%-4% of patients treated for year; these trends continue with longer duration of use. Also can increase blood pressure and induce kidney injury. \nRisks are dose related.\nIncreased risk of gastrointestinal bleeding/peptic ulcer disease and acute kidney injury in older adults', 'Recommendation': 'Avoid', 'Quality of Evidence': 'tablets:', 'Strenght of Recommendation': 'weak'}
{'_id': ObjectId('65cce52f16de1163e69b7e8e'), 'Organ System, Therapeutic Category, Drug(s)': ['Pain medications', ['Skeletal muscle relaxants', ['Chlorzoxazone', 'Cyclobenzaprine', 'Metaxalone', 'Methocarbamol', 'Orphenadrine']]], 'Rationale': 'Indomethacin is more likely than other NSAIDs to have adverse CNS effects. Of all the NSAIDs, indomethacin has the most adverse effects.\nMost muscle relaxants poorly tolerated by older adults because some have anticholinergic adverse effects, sedation, increased risk of fractures; effectiveness at dosages tolerated by older adults questionable', 'Recommendation': 'Avoid', 'Quality of Evidence': 'High', 'Strenght of Recommendation': 'Strong'}
{'_id': ObjectId('65cce52f16de1163e69b7e8f'), 'Organ System, Therapeutic Category, Drug(s)': ['Genitourinary', ['Desmopressin', []]], 'Rationale': 'High risk of hyponatremia; safer alternative treatments', 'Recommendation': 'Avoid for treatment of nocturia or nocturnal polyuria', 'Quality of Evidence': 'Moderate', 'Strenght of Recommendation': 'Strong'}
